| 摘要 |
Distinct epitopes of HSP60 are identified to modulate binding and activation of macrophages. One epitope, localized to residues 335-366, and more specifically to residues 254-265, of human HSP60 binds LPS and by presenting it to toll receptor-4 complex immunostimulates the cells, and a second epitope, localized to residues 481-500 of HSP60, is responsible for binding to the macrophage cell surface. The present invention relates to novel compounds, capable of inhibiting the binding of those peptidic regions to LPS or to macrophages. The present invention further relates to pharmaceutical compositions comprising these novel compounds, useful for prevention or treatment of inflammatory and autoimmune diseases and disorders.<SUP/> |
